Novo Nordisk has appointed Maziar Mike Doustdar as CEO, replacing Lars Fruergaard, to address recent market challenges.

Novo Nordisk’s shock profit downgrade and 22% share price plunge spooked global markets. But for ResMed shareholders, the ...

Novo Nordisk shares plunged more than 20% on the 29th (local time) in New York and Denmark on the 29th (local time) due to the announcement of a slowdown in sales growth of the obesity drug "Wegovy".

Shares in Asia are mostly higher after the U.S. and China ended their latest round of trade talks without a deal ...